Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Asset Writedowns and Impairment: 2014-2018

Historic Asset Writedowns and Impairment for Ironwood Pharmaceuticals (IRWD) over the last 4 years, with Dec 2018 value amounting to $151.8 million.

  • Ironwood Pharmaceuticals' Asset Writedowns and Impairment was N/A to $6,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $154.0 million, marking a year-over-year change of. This contributed to the annual value of $151.8 million for FY2018, which is N/A change from last year.
  • According to the latest figures from FY2018, Ironwood Pharmaceuticals' Asset Writedowns and Impairment is $151.8 million, which was up 40,488.24% from $374,000 recorded in FY2016.
  • Ironwood Pharmaceuticals' 5-year Asset Writedowns and Impairment high stood at $151.8 million for FY2018, and its period low was $374,000 during FY2016.
  • For the 2-year period, Ironwood Pharmaceuticals' Asset Writedowns and Impairment averaged around $76.1 million, with its median value being $76.1 million (2016).
  • Data for Ironwood Pharmaceuticals' Asset Writedowns and Impairment shows a maximum YoY crashed of 97.88% (in 2016) over the last 5 years.
  • Yearly analysis of 4 years shows Ironwood Pharmaceuticals' Asset Writedowns and Impairment stood at $20.3 million in 2014, then fell by 13.08% to $17.6 million in 2015, then crashed by 97.88% to $374,000 in 2016, then reached $151.8 million in 2018.